Ramucirumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ramucirumab: From Unknown Original Indication to Uterine Ligament Adenocarcinoma
One-Sentence Summary
Ramucirumab is an anti-VEGFR2 monoclonal antibody; its original approved indication in India is not currently on record in this evidence pack. The TxGNN model predicts potential activity against Uterine Ligament Adenocarcinoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests entirely on algorithmic inference and class-effect reasoning.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no India license data on file) |
| Predicted New Indication | Uterine Ligament Adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| India Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for Ramucirumab in this evidence pack. Based on known pharmacology, Ramucirumab is an anti-VEGFR2 monoclonal antibody belonging to the antiangiogenic drug class, mechanistically related to agents like bevacizumab.
The repurposing rationale draws on class-effect reasoning: anti-VEGF/VEGFR2 agents have demonstrated efficacy in cervical cancer (e.g., bevacizumab in the GOG-240 trial), which provides a theoretical basis for potential activity in gynecologic adenocarcinomas. However, this is an indirect, analogy-based inference rather than direct evidence for Ramucirumab specifically in uterine ligament adenocarcinoma — a rare histological subtype with no published data on VEGFR2 expression or angiogenesis dependence.
The strength of this rationale should not be overstated: it is biologically plausible but entirely unproven for this specific drug-indication pair. All ten top-ranked predictions in this evidence pack share this same limitation — high TxGNN confidence scores paired with zero direct clinical or literature support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Ramucirumab is not currently marketed in India (0 registered licenses on file). No authorization records are available.
Cytotoxicity
Ramucirumab is classified as a targeted antineoplastic agent (anti-VEGFR2 monoclonal antibody), meeting the antineoplastic criteria via its known drug class.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (VEGFR2-targeted monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Drug Interactions: Ramucirumab has 127 recorded drug-drug interactions. Notable Major-severity interactions include:
- Acetylsalicylic acid
- Deferasirox
- Ibritumomab tiuxetan
- Tositumomab (I-131) / Tositumomab
- Abciximab
- Alteplase
- Antithrombin III human
- Apixaban
- Betrixaban
- Bivalirudin
- Cangrelor
- Caplacizumab
- Cilostazol
- Clopidogrel
- Dalteparin
- Defibrotide
Many of these are antiplatelet, anticoagulant, or thrombolytic agents, consistent with Ramucirumab’s known antiangiogenic bleeding-risk profile — caution is warranted when co-administering agents that further increase bleeding risk.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by a TxGNN model score with no corroborating clinical trials or literature (Evidence Level L5), and the drug is not currently marketed in India. Combined with critical safety and regulatory data gaps, this candidate does not meet the threshold for further development at this time.
To proceed, the following is needed:
- India (TFDA-equivalent) label warnings and contraindications (currently blocking — DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Original approved indication(s) for Ramucirumab in India
- Preclinical or translational evidence of VEGFR2 relevance in uterine ligament adenocarcinoma specifically
- Any case reports or off-label use data in gynecologic adenocarcinomas before considering further investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.